HALO – halozyme therapeutics, inc. (US:NASDAQ)
Stock Stats
News
How Halozyme's ENHANZE–Vedolizumab Deal With Takeda At Halozyme Therapeutics (HALO) Has Changed Its Investment Story [Yahoo! Finance]
Is Halozyme Therapeutics (HALO) Pricing Reflect Its DCF And P/E Signals After Recent Gains [Yahoo! Finance]
HALO or AXSM: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE® [Yahoo! Finance]
Halozyme Therapeutics (NASDAQ:HALO) had its price target raised by analysts at TD Cowen from $79.00 to $90.00. They now have a "buy" rating on the stock.
Form 4 HALOZYME THERAPEUTICS, For: Jan 02 Filed by: Lang James Paul
Form 4 HALOZYME THERAPEUTICS, For: Jan 05 Filed by: Connaughton Bernadette
Form 4 HALOZYME THERAPEUTICS, For: Jan 03 Filed by: Snyder Mark Howard
Form 3 HALOZYME THERAPEUTICS, For: Dec 04 Filed by: Lang James Paul
Form 144 HALOZYME THERAPEUTICS, Filed by: Connaughton Bernadette
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.